Agilent supports cancer research center
Dr Ronald A. DePinho ? president of the University of Texas MD Anderson Cancer Center (Texas, USA) ? has received an Agilent Thought Leader Award.
Dr Ronald A. DePinho — president of the University of Texas MD Anderson Cancer Center (Texas, USA) — has received an Agilent Thought Leader Award. Agilent Technologies (California, USA) will provide financial support for personnel as well as instrumentation for the center.
The work of DePinho has resulted in the development of improved cancer detection methods and cancer drug development. His research group focuses broadly on basic‑to‑translational research programmes for brain, colorectal, pancreas and prostate cancers, as well as ageing and neuro‑degeneration.
The award will support DePinho and his team in their research into reprogramming the metabolome at the initial stages of cancer. Specifically, the instrumentation will “enhance” the investigation of metabolic adaptions during the development of pancreatic cancer, according to Dr Guilio Draetta, director of the Institute for Applied Cancer Science.
Pancreatic cancer is a major concern of DePinho’s group because survival rates of patients have not significantly improved over the past two decades. Depinho said: “This technology will allow us to rapidly identify new targets that drive the formation, progression and maintenance of pancreatic cancer. Discoveries from this research will also lead to the development of effective early detection biomarkers and novel therapeutic interventions.”
Patrick Kaltenbach, Agilent VP and general manager of the Liquid Phase division, said: “We are proud to support Dr DePinho’s exciting translational research programme, which will make use of metabolomics and integrated biology workflows and solutions in biomarker discovery.”
Draetta added: “Armed with novel biomarkers, earlier diagnosis and treatment will be possible, leading to improved patient outcomes. Additional opportunities for novel therapeutic intervention will also emerge from this work.”
For more information please visit:
www.agilent.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
